DelNova, Inc. is a biopharmaceutical company focused on addressing unmet medical needs. DelNova is resolving complications arising from botulinum toxin therapies (eg. Botox®). The first product under development, ReViVox™ is based on a clinically validated drug currently approved for a different medical use and route of administration. The novel formulation will manage undesirable side effects resulting from neurotoxin injections in both medical and cosmetic applications.
Petra Capital Properties is a mission-based real estate investment management company dedicated to serving their clients with high quality real estate investment opportunities with...
Embrace Prevention Care provides Personal Prevention Care to older adults with heart failure and other chronic conditions to help them take healthy actions that...
